Several major hedge funds are poised to benefit if Acelyrin’s offering is successful.
Stephen TaubApril 24, 2023
Another fledgling biopharma company is looking to test the IPO market — and several well-known hedge funds hope to reap the benefits. Acelyrin, a late-stage clinical biopharma company focused on “transformative medicines,” recently filed plans to
To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.